Exact Therapeutics AS, a clinical stage Norway-based biotech company, has named Dr Rafiq Hasan as its new CEO, it was reported on Wednesday.

Dr Hasan has held senior positions with Bayer and Novartis. He was SVP and global head of Ophthalmology at Bayer most recently. He joins as the GE Healthcare spin-out, formerly known as Phoenix Solutions, reports strong progress in its First in Man ACTivate-trial (NCT04021277), investigating ACT combination with standard of care chemotherapy for the treatment of hepatic metastases secondary to colorectal and pancreatic cancers.

Sir William Castell, vice-chairman of EXACT Therapeutics, said, 'We are thrilled to attract a world-leading pharma professional and physician of Rafiq's stature, to propel EXACT to the next level of achievement. Encouraged by the initial results of our ongoing Phase I trial, we are progressing towards our Phase II. Rafiq joins us at a critical time when we are increasingly focused on the commercial potential for Acoustic Cluster Therapy (ACT). His in-depth appreciation of clinical development, market access and commercialisation will be invaluable in successfully driving forward the ACT platform.'